Martien van Osch, MSc
Martien is a founding partner at Forbion Capital Partners and acts as its CFO.
He splits his time between investment related activities and the finance function. In terms of investment focus, Martien spearheads the medical device related activities at Forbion. He was responsible for the recent exit Santaris Pharma AS to Roche in August 2014 for up to USD 450 million, the sale of Circulite inc to Heartware inc in December 2013 for up to USD 350 million and of Pathway Medical Technologies, Inc., sold to Bayer Medrad in 2011 for USD 125 million. He currently actively contributes to the boards of Mitralign Inc. and PneumRx, Inc.His experience in the life sciences industry also includes prior non-executive board positions at Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), Impella Cardiosystems (sold to Abiomed, Inc. in 2005), Acadia Pharmaceuticals (IPO on Nasdaq in 2004) and Flowmedica, Inc. (sold to Angiodynamics in 2009). Martien holds a degree in Econometrics from the Rijksuniversiteit Groningen, the Netherlands.